{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T13:57:26Z","timestamp":1693663046246},"reference-count":55,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":26,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"name":"Taiwan National Science Council Fellowship","award":["102-2917-I-564-013"],"award-info":[{"award-number":["102-2917-I-564-013"]}]},{"name":"Health Delivery Systems Center for Diabetes Translational Research","award":["1P30-DK092924"],"award-info":[{"award-number":["1P30-DK092924"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiol Drug Saf"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1002\/pds.3834","type":"journal-article","created":{"date-parts":[[2015,8,6]],"date-time":"2015-08-06T15:40:15Z","timestamp":1438875615000},"page":"1026-1035","source":"Crossref","is-referenced-by-count":8,"title":["Effects of safety warnings and risk management plan for Thiazolidinediones in Taiwan"],"prefix":"10.1002","volume":"24","author":[{"given":"Jason C.","family":"Hsu","sequence":"first","affiliation":[{"name":"School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine; National Cheng Kung University; Tainan Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Lan","family":"Cheng","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine; National Cheng Kung University; Tainan Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Ross-Degnan","sequence":"additional","affiliation":[{"name":"Department of Population Medicine; Harvard Medical School and Harvard Pilgrim Health Care Institute; Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita K.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Department of Population Medicine; Harvard Medical School and Harvard Pilgrim Health Care Institute; Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Population Medicine; Harvard Medical School and Harvard Pilgrim Health Care Institute; Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yea-Huei","family":"Kao Yang","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine; National Cheng Kung University; Tainan Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Ling","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Drug; Food and Drug Administration, Ministry of Health and Welfare; Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsueh-Yung","family":"Tai","sequence":"additional","affiliation":[{"name":"Division of Drug; Food and Drug Administration, Ministry of Health and Welfare; Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke-Hsin","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Drug; Food and Drug Administration, Ministry of Health and Welfare; Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Wen","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Drug; Food and Drug Administration, Ministry of Health and Welfare; Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine Y.","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Population Medicine; Harvard Medical School and Harvard Pilgrim Health Care Institute; Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,8,6]]},"reference":[{"issue":"6","key":"10.1002\/pds.3834-BIB0001|pds3834-cit-0001","doi-asserted-by":"crossref","first-page":"523","DOI":"10.18553\/jmcp.2008.14.6.523","article-title":"Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events","volume":"14","author":"Starner","year":"2008","journal-title":"J Manag Care Pharm"},{"issue":"1","key":"10.1002\/pds.3834-BIB0002|pds3834-cit-0002","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2337\/dc08-9016","article-title":"Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes","volume":"31","author":"Nathan","year":"2008","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1002\/pds.3834-BIB0003|pds3834-cit-0003","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2337\/dc09-1834","article-title":"Changes in glitazone use among office-based physicians in the U.S., 2003-2009","volume":"33","author":"Cohen","year":"2010","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/pds.3834-BIB0004|pds3834-cit-0004","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"issue":"9 Suppl 2","key":"10.1002\/pds.3834-BIB0005|pds3834-cit-0005","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.amjmed.2007.07.004","article-title":"Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus","volume":"120","author":"Fonseca","year":"2007","journal-title":"Am J Med"},{"issue":"23","key":"10.1002\/pds.3834-BIB0006|pds3834-cit-0006","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1002\/pds.3834-BIB0007|pds3834-cit-0007","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/11596950-000000000-00000","article-title":"Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008","volume":"35","author":"Ruiter","year":"2012","journal-title":"Drug Saf"},{"issue":"2","key":"10.1002\/pds.3834-BIB0008|pds3834-cit-0008","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3233\/JRS-2012-0559","article-title":"The rosiglitazone decision process at FDA and EMA. What should we learn?","volume":"24","author":"Pouwels","year":"2012","journal-title":"Int J Risk Saf Med"},{"issue":"24","key":"10.1002\/pds.3834-BIB0009|pds3834-cit-0009","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1002\/pds.3834-BIB0010|pds3834-cit-0010","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4330\/wjc.v3.i5.144","article-title":"PPARgamma activator, rosiglitazone: is it beneficial or harmful to the cardiovascular system?","volume":"3","author":"Palee","year":"2011","journal-title":"World J Cardiol"},{"issue":"7606","key":"10.1002\/pds.3834-BIB0011|pds3834-cit-0011","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/bmj.39245.502546.BE","article-title":"Rosiglitazone and implications for pharmacovigilance","volume":"334","author":"Kazi","year":"2007","journal-title":"Br Med J"},{"issue":"4","key":"10.1002\/pds.3834-BIB0012|pds3834-cit-0012","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jama.2010.920","article-title":"Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone","volume":"304","author":"Graham","year":"2010","journal-title":"JAMA"},{"issue":"7","key":"10.1002\/pds.3834-BIB0013|pds3834-cit-0013","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/eurheartj\/ehq016","article-title":"The rise and fall of rosiglitazone","volume":"31","author":"Nissen","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1002\/pds.3834-BIB0014|pds3834-cit-0014","unstructured":"FDA Information for Healthcare Professionals Rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandaryl) http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm143406.htm"},{"key":"10.1002\/pds.3834-BIB0015|pds3834-cit-0015","unstructured":"FDA Information for Healthcare Professionals Rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandaryl) http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm143460.htm"},{"issue":"1","key":"10.1002\/pds.3834-BIB0016|pds3834-cit-0016","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.diabres.2011.02.035","article-title":"Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert","volume":"93","author":"Hurren","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1002\/pds.3834-BIB0017|pds3834-cit-0017","unstructured":"EMA EMEA statement on recent publication on cardiac safety of rosiglitazone (Avandia, Avandamet, Avaglim) http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2009\/11\/WC500013467.pdf"},{"key":"10.1002\/pds.3834-BIB0018|pds3834-cit-0018","unstructured":"EMA European Medicines Agency confirms positive benefit-risk balance for rosiglitazone and pioglitazone http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2009\/11\/WC500011009.pdf"},{"key":"10.1002\/pds.3834-BIB0019|pds3834-cit-0019","unstructured":"EMA EMEA recommends new warnings and contraindications for rosiglitazone http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2009\/11\/WC500015420.pdf"},{"key":"10.1002\/pds.3834-BIB0020|pds3834-cit-0020","unstructured":"Taiwan Bureau of Pharmaceutical Affairs press release http:\/\/life.dwnews.com\/big5\/news\/2007-07-31\/3132407.html"},{"key":"10.1002\/pds.3834-BIB0021|pds3834-cit-0021","unstructured":"Actos (pioglitazone) package insert. Research Triangle Park, NC: GlaxoSmithKline 2009"},{"key":"10.1002\/pds.3834-BIB0022|pds3834-cit-0022","unstructured":"Avandia (rosiglitazone) package insert. Research Triangle Park, NC: GlaxoSmithKline 2008"},{"key":"10.1002\/pds.3834-BIB0023|pds3834-cit-0023","unstructured":"FDA News 2007 www.fda.gov\/bbs\/topics\/NEWS\/2007\/NEW01683.html"},{"key":"10.1002\/pds.3834-BIB0024|pds3834-cit-0024","unstructured":"FDA prescribing information of Avandia (rosiglitazone maleate) http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM143413.pdf"},{"issue":"10","key":"10.1002\/pds.3834-BIB0025|pds3834-cit-0025","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","article-title":"Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials","volume":"298","author":"Lincoff","year":"2007","journal-title":"JAMA"},{"key":"10.1002\/pds.3834-BIB0026|pds3834-cit-0026","doi-asserted-by":"crossref","first-page":"b2942","DOI":"10.1136\/bmj.b2942","article-title":"Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study","volume":"339","author":"Juurlink","year":"2009","journal-title":"Br Med J"},{"issue":"14","key":"10.1002\/pds.3834-BIB0027|pds3834-cit-0027","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archinternmed.2010.207","article-title":"Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality","volume":"170","author":"Nissen","year":"2010","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1002\/pds.3834-BIB0028|pds3834-cit-0028","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1345\/aph.1Q400","article-title":"Rosiglitazone, myocardial ischemic risk, and recent regulatory actions","volume":"46","author":"Bourg","year":"2012","journal-title":"Ann Pharmacother"},{"issue":"9681","key":"10.1002\/pds.3834-BIB0029|pds3834-cit-0029","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/pds.3834-BIB0030|pds3834-cit-0030","unstructured":"FDA significantly restricts access to the diabetes drug Avandia http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm226956.htm"},{"issue":"16","key":"10.1002\/pds.3834-BIB0031|pds3834-cit-0031","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMp1010788","article-title":"Regulatory action on rosiglitazone by the U.S. Food and Drug Administration","volume":"363","author":"Woodcock","year":"2010","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1002\/pds.3834-BIB0032|pds3834-cit-0032","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1056\/NEJMp1011042","article-title":"Responding to an FDA warning-geographic variation in the use of rosiglitazone","volume":"363","author":"Shah","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1002\/pds.3834-BIB0033|pds3834-cit-0033","unstructured":"Medication guide. Avandia (rosiglitazone maleate tablets) 2011 www.fda.gov\/downloads\/Drugs\/DrugSafety\/ucm085922.pdf"},{"key":"10.1002\/pds.3834-BIB0034|pds3834-cit-0034","unstructured":"EMA European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim [media release]. EMA\/585784\/2010. 2010 Sep 23[online] http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2010\/09\/news_detail_001119.jsp&mid=WC0b01ac058004d5c1&jsenabled=true"},{"issue":"9493","key":"10.1002\/pds.3834-BIB0035|pds3834-cit-0035","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/pds.3834-BIB0036|pds3834-cit-0036","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00002018-200932030-00002","article-title":"Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive","volume":"32","author":"Dormandy","year":"2009","journal-title":"Drug Saf"},{"issue":"4","key":"10.1002\/pds.3834-BIB0037|pds3834-cit-0037","doi-asserted-by":"crossref","first-page":"916","DOI":"10.2337\/dc10-1068","article-title":"Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study","volume":"34","author":"Lewis","year":"2011","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/pds.3834-BIB0038|pds3834-cit-0038","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2125.2012.04325.x","article-title":"Pioglitazone and bladder cancer: a propensity score matched cohort study","volume":"75","author":"Li","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"10.1002\/pds.3834-BIB0039|pds3834-cit-0039","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/cncr.25641","article-title":"Diabetes and risk of bladder cancer: evidence from a case-control study in New England","volume":"117","author":"MacKenzie","year":"2011","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/pds.3834-BIB0040|pds3834-cit-0040","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.diabres.2012.05.006","article-title":"Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis","volume":"98","author":"Zhu","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"issue":"7","key":"10.1002\/pds.3834-BIB0041|pds3834-cit-0041","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s00125-012-2538-9","article-title":"Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study","volume":"55","author":"Neumann","year":"2012","journal-title":"Diabetologia"},{"key":"10.1002\/pds.3834-BIB0042|pds3834-cit-0042","unstructured":"FDA drug safety communication: ongoing safety review of actos (pioglitazone) and potential increased risk of bladder cancer after two years exposure. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm226214.htm"},{"key":"10.1002\/pds.3834-BIB0043|pds3834-cit-0043","unstructured":"USFDA-Website(2) http:\/\/www.fda.gov\/drugs\/drugsafety\/ucm259150.htm"},{"issue":"3","key":"10.1002\/pds.3834-BIB0044|pds3834-cit-0044","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jdiacomp.2010.06.003","article-title":"Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus","volume":"25","author":"Shi","year":"2011","journal-title":"J Diabetes Complications"},{"issue":"2-3","key":"10.1002\/pds.3834-BIB0045|pds3834-cit-0045","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.healthpol.2013.11.005","article-title":"Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: an interrupted time series study","volume":"116","author":"Hsu","year":"2014","journal-title":"Health Policy"},{"issue":"4","key":"10.1002\/pds.3834-BIB0046|pds3834-cit-0046","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research","volume":"27","author":"Wagner","year":"2002","journal-title":"J Clin Pharm Ther"},{"key":"10.1002\/pds.3834-BIB0047|pds3834-cit-0047","doi-asserted-by":"crossref","first-page":"g3596","DOI":"10.1136\/bmj.g3596","article-title":"Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study","volume":"348","author":"Lu","year":"2014","journal-title":"Br Med J"},{"issue":"1","key":"10.1002\/pds.3834-BIB0048|pds3834-cit-0048","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/MLR.0b013e3181bd4c10","article-title":"Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness","volume":"48","author":"Lu","year":"2010","journal-title":"Med Care"},{"issue":"2","key":"10.1002\/pds.3834-BIB0049|pds3834-cit-0049","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jclinepi.2008.08.007","article-title":"Methods for estimating confidence intervals in interrupted time series analyses of health interventions","volume":"62","author":"Zhang","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1002\/pds.3834-BIB0050|pds3834-cit-0050","unstructured":"Allison PD Survival analysis using SAS: a practical guide Cary , NC , SAS Institute 1995"},{"issue":"2","key":"10.1002\/pds.3834-BIB0051|pds3834-cit-0051","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1176\/ps.62.2.pss6202_0186","article-title":"Association between prior authorization for medications and health service use by Medicaid patients with bipolar disorder","volume":"62","author":"Lu","year":"2011","journal-title":"Psychiatr Serv"},{"issue":"5","key":"10.1002\/pds.3834-BIB0052|pds3834-cit-0052","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/11599100-000000000-00000","article-title":"Impact of safety-related regulatory action on clinical practice: a systematic review","volume":"35","author":"Piening","year":"2012","journal-title":"Drug Saf"},{"issue":"6","key":"10.1002\/pds.3834-BIB0053|pds3834-cit-0053","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/MLR.0b013e318245a160","article-title":"Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review","volume":"50","author":"Dusetzina","year":"2012","journal-title":"Med Care"},{"issue":"10","key":"10.1002\/pds.3834-BIB0054|pds3834-cit-0054","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1001\/jama.298.10.1189","article-title":"Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis","volume":"298","author":"Singh","year":"2007","journal-title":"JAMA"},{"key":"10.1002\/pds.3834-BIB0055|pds3834-cit-0055","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1472-6963-8-75","article-title":"Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature-2001-2007","volume":"8","author":"Lu","year":"2008","journal-title":"BMC Health Serv Res"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.3834","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/pds.3834","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T23:06:36Z","timestamp":1599433596000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/pds.3834"}},"subtitle":["Impacts of Thiazolidinedione's Safety Regulatory Actions in Taiwan"],"short-title":[],"issued":{"date-parts":[[2015,8,6]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"URL":"https:\/\/doi.org\/10.1002\/pds.3834","archive":["Portico"],"relation":{},"ISSN":["1053-8569"],"issn-type":[{"value":"1053-8569","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8,6]]}}}